Effect of cervus and cucumis polypeptide combined with zoledronic acid on bone metabolic biochemical markers in glucocorticoids-Induced osteoporosis patients

Abstract EN

bone metabolic biochemical markers in glucocorticoids - induced osteoporosis patients.

Methods: A total of 100 patients with glucocorticoids - induced osteoporosis admitted to our hospital from January 2015 to June 2017 were enrolled in this study.

Patients were divided into observation group and control group by random number table method, 50 cases in each group.

Patients in the observation group were treated with deer melon polypeptide in combination with zoledronic acid, and patients in the control group were treated with zoledronic acid alone.

The patients in both groups were treated for 2 months.

The changes of bone mineral density (BMD) and biochemical markers of bone metabolism in lumbar vertebrae L1-4, left femoral neck and large trochanter were analyzed before and after treatment.

Results: The pre- BMD at lumbar spine L1-4, left femoral neck and great trochanter had no statistic difference (P > 0.05), the BMD at each sites improved after treatment, and the difference were statistical before and after treatment (P < 0.05).

BMD at above sites of two groups after treatment had statistical difference (P < 0.05), and the BMD at lumbar spine L1-4, left femoral neck and great trochanter in the observation group was higher than that of the control group.

There were no significant differences in PTH, 25-(OH) D3, TRACP, b-CTX and BGP levels between the two groups before treatment (P > 0.05).

The levels of 25-(OH)D3, TRACP, b-CTX and BGP in the two groups were significantly improved after treatment (P < 0.05), and the levels of PTH, TRACP and b-CTX in the observation group were significantly lower than those in the control group.

The levels of 25-(OH) D3 and BGP were significantly higher than those of the control group (P < 0.05).

Conclusion: The cervus and cucumis polypeptide combined with zoledronic acid can improve the BMD at lumbar spine L1-4, left femoral neck and great trochanter, and ameliorate the bone metabolic biochemical markers for patients with glucocorticoids - induced osteoporosis.